A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

@article{Wallace2009API,
  title={A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.},
  author={Daniel J Wallace and William Stohl and Richard A. Furie and Jeffrey R Lisse and J. D. McKay and Joan T. Merrill and Michelle A. Petri and Ellen M Ginzler and W. Winn Chatham and W. J. Mccune and Vivian Fernandez and Marc R Chevrier and Z. John Zhong and William W. Freimuth},
  journal={Arthritis and rheumatism},
  year={2009},
  volume={61 9},
  pages={
          1168-78
        }
}
OBJECTIVE To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >/=4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo in a 52-week study. Coprimary end… 

Figures and Tables from this paper

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
TLDR
Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
TLDR
In this phase II trial, belimumab demonstrated efficacy and was generally well tolerated in patients with RA who had failed previous therapies, and adverse event rates were similar across treatment groups.
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
TLDR
Disease control and safety profile were maintained in patients with active SLE taking belimumab plus standard therapy for up to 7 years, and serious and overall annual AE rates were generally stable or decreased during 7-year treatment.
Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials
TLDR
Belimumab at 1 and 10 mg/kg IV and belimumab 200‬mg SC in combination with standard therapy was an efficacious intervention for active SLE, and was not associated with a significant risk of SAEs.
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
TLDR
Treatment with intravenous sirukumab infusions was generally well tolerated in both cutaneous lupus erythematosus patients with mild, stable, active disease and linear pharmacokinetics in CLE and SLE patients was demonstrated.
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
TLDR
PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE and evidence of an effect with 10 mg was seen in a post hoc analysis.
Novel evidence-based systemic lupus erythematosus responder index.
TLDR
This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
TLDR
The preliminary safety, PK profile, and observed biological activity of belimumab support further evaluation of its safety and efficacy in Japanese patient with SLE.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Novel evidence-based systemic lupus erythematosus responder index.
TLDR
This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
TLDR
Belimumab was well tolerated and reduced peripheral B-cell levels in SLE patients and these data support further studies of belimumab in autoimmune disorders.
A trial of contraceptive methods in women with systemic lupus erythematosus.
TLDR
Global disease activity, maximum SLEDAI score, incidence of flares, time to first flare, and incidence of adverse events were similar among women with systemic lupus erythematosus, irrespective of the type of contraceptive they were using.
The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial
TLDR
This multicenter, double-blind trial found no significant difference in flare rate between HRT and placebo groups, and health issues specific to women warrant attention and need to be confronted in patients with SLE.
Combined Oral Contraceptives in Women With Systemic Lupus Erythematosus
TLDR
This study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable and is within the prespecified 9 percent margin for noninferiority.
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
TLDR
The results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE, and a relationship between circulatingBLyS levels and SLE disease activity is demonstrated.
Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies
TLDR
Sustained reductions in anti-double-stranded DNA antibodies, regardless of treatment group, led to clinically meaningful improvements in patient-reported health-related quality of life.
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
  • W. Halpern, P. Lappin, K. Baker
  • Biology, Medicine
    Toxicological sciences : an official journal of the Society of Toxicology
  • 2006
TLDR
Data confirm the specific pharmacologic activity of belimumab in reducing B lymphocytes in the cynomolgus monkey, and the favorable safety profile and lack of treatment-related infections also support continued clinical development ofBelimumab.
Definition and treatment of lupus flares measured by the BILAG index.
TLDR
Results are consistent with the principles upon which the BILAG index was devised and suggest that a moderate disease flare can be defined as a new B score following a C, D or E score according to the B ILAG index.
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
TLDR
OBJECTIVE Autoantibody production in patients with systemic lupus erythematosus (SLE) is associated with abnormalities of B cell function and phenotype, and clinical responses to B cell depletion therapy (BCDT), based on rituximab, are encouraging, suggests that B cell clones committed to producing antinucleosome and anti-dsDNA antibodies have a relatively rapid turnover compared with B cell clone producing other antibodies.
...
...